Keywords: phase, iii, data, shows, superiority, enzon, peg-intron
Phase III data shows superiority of Enzon's PEG-Intron
Article | 19 April 2000
Enzon's pegylated form of Schering-Plough's Intron A (recombinantinterferon alfa-2b) has proved more effective than the original as a monotherapy ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
